HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

California ephedrine

This article was originally published in The Tan Sheet

Executive Summary

Assembly bill No. 2294, introduced Feb. 24 by Susan Davis (D), would prohibit the sale or distribution of dietary supplements containing ephedrine unless labeling warns about potential adverse reactions and contraindications and states people under 18 should not take the product. The bill also would require labeling bear a toll-free number consumers could call to report adverse effects to the State Department of Health Services. The bill's introduction follows a February "informational" hearing chaired by Davis, whose district is in San Diego, where Metabolife International, manufacturer of the ephedra supplement Metabolife 356, is located. Similar measures are being considered by Texas and New York City; comments on the Texas proposed regs are due by April 4 (1"The Tan Sheet" Feb. 28, In Brief)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

RS133885

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel